AKT1 and B-cell chronic lymphocytic leukemia: mTOR inhibitors, PI3K inhibitors (PI3Ki), dual PI3K–mTOR inhibitors and AKT inhibitors are approved in different settings such as advanced RCC (temsirolimus and everolumus), advanced ER+ BC (alpelisib and everolimus) and chronic lymphatic leukemia (CLL) (idelalisib) [84].